Cart
sales@molnova.com
Glucagon-like peptide 1 (1-37), human TFA
CAS No. ———
Glucagon-like peptide 1 (1-37), human TFA( ——— )
Catalog No. M40549 CAS No. ———
Glucagon-like peptide 1 (1-37), human (TFA) is a highly potent agonist of the GLP-1 receptor, it is a kind of pancreatic hormone synthesized by post-translational processing of proglucagon.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | Get Quote | Get Quote |
|
| 50MG | Get Quote | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameGlucagon-like peptide 1 (1-37), human TFA
-
NoteResearch use only, not for human use.
-
Brief DescriptionGlucagon-like peptide 1 (1-37), human (TFA) is a highly potent agonist of the GLP-1 receptor, it is a kind of pancreatic hormone synthesized by post-translational processing of proglucagon.
-
DescriptionGlucagon-like peptide 1 (1-37), human (TFA) is a highly potent agonist of the GLP-1 receptor, it is a kind of pancreatic hormone synthesized by post-translational processing of proglucagon.
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
Recptor———
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number———
-
Formula Weight———
-
Molecular Formula———
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
(7R,8R)-Dihydrodehyd...
(7R,8R)-Dihydrodehydrodiconiferyl alcohol 9-O-β-D-glucoside is a Lignans product that can be isolated from the herbs of Lysimachia clethroides.
-
(R)-O-isobutyroyllom...
(R)-O-isobutyroyllomatin shows significant dose-dependent protection against oxidative stress, it also exhibits cell proliferative effects.
-
APOL1-IN-1
APOL1-IN-1 is a potent inhibitor of apolipoprotein L1 (APOL1) that can be used to study the pathogenesis of focal segmental glomerulosclerosis (FSGS) and nondiabetic kidney disease (NDKD), facilitating research into these diseases.
